Dell today announced its extended partnership with Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world’s first Food and Drug Administration (FDA)-approved personalized medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support the Neuroblastoma and Medulloblastoma Translational Research Consortium’s (NMTRC) expanded pediatric cancer clinical trials in EMEA, starting with sites in France and Lebanon. This is the second grant Dell has provided TGen to accelerate treatment of pediatric cancer, bringing its total contributions to more than $15 million since 2011.
Dell and TGen Support Fight Against Pediatric Cancer Across EMEA | Dell
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.